Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Randomized controlled study of inactivated tick-borne encephalitis vaccine in people aged 8 years and older
ChiCTR2200059830Phase 4Not yet recruiting
- Sponsor
- Inner Mongolia Autonomous Region Center for Disease Prevention and Control
- Start
- May 2022
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 4, randomised trial of tick-borne encephalitis vaccine, inactivated and Quadrivalent influenza split vaccine (Changchun Sponsor Institute of Biological Products) in tick-borne encephalitis (TBE) (2 arms), sponsored by Inner Mongolia Autonomous Region Center for Disease Prevention and Control. Primary endpoints: Neutralization antibody level, Seropositivity and 1 more. Planned start May 2022; status: not yet recruiting.
02
Drugs
tick-borne encephalitis vaccine, inactivatedQuadrivalent influenza split vaccine (Changchun Sponsor Institute of Biological Products)
03
Conditions
tick-borne encephalitis (TBE)
Beyond the preview
Go deeper on ChiCTR2200059830.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200059830.